Evidence map›Paper›PMID 26263483›Full record

ArticleBritish journal of cancer2015

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.

Michaela B Kirschner, Emily Pulford, Mir Alireza Hoda, Anita Rozsas, Kim Griggs, Yuen Yee Cheng, J James B Edelman, Steven C Kao, Rebecca Hyland, Yawen Dong and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Michaela B KirschnerAsbestos Diseases Research Institute (ADRI), Sydney, NSW 2139, Australia.
Emily PulfordDepartment of Anatomical Pathology, Flinders University and SA Pathology, Adelaide, SA 5042, Australia.
Mir Alireza HodaTranslational Thoracic Oncology Laboratory, Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria.
Anita RozsasTranslational Thoracic Oncology Laboratory, Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria.
Kim GriggsDepartment of Anatomical Pathology, Flinders University and SA Pathology, Adelaide, SA 5042, Australia.
Yuen Yee ChengAsbestos Diseases Research Institute (ADRI), Sydney, NSW 2139, Australia.
J James B EdelmanCardiothoracic Surgical Unit, Royal Prince Alfred Hospital; The Baird Institute; The University of Sydney, Sydney, NSW 2050, Australia.
Steven C KaoAsbestos Diseases Research Institute (ADRI), Sydney, NSW 2139, Australia.
Rebecca HylandAsbestos Diseases Research Institute (ADRI), Sydney, NSW 2139, Australia.
Yawen DongTranslational Thoracic Oncology Laboratory, Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria.
Viktoria LászlóTranslational Thoracic Oncology Laboratory, Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria.
Thomas KlikovitsTranslational Thoracic Oncology Laboratory, Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria.
Michael P VallelySydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia.
Michael GruschDepartment of Medicine I, Institute of Cancer Research, Medical University of Vienna, 1090 Vienna, Austria.
Balazs HegedusTranslational Thoracic Oncology Laboratory, Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria.
Balazs DomeTranslational Thoracic Oncology Laboratory, Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria.
Walter KlepetkoTranslational Thoracic Oncology Laboratory, Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria.
Nico van ZandwijkAsbestos Diseases Research Institute (ADRI), Sydney, NSW 2139, Australia.
Sonja KlebeDepartment of Anatomical Pathology, Flinders University and SA Pathology, Adelaide, SA 5042, Australia.
Glen ReidAsbestos Diseases Research Institute (ADRI), Sydney, NSW 2139, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFibulin-3 (FBLN3) was recently presented as a promising novel biomarker for malignant pleural mesothelioma (MPM), warranting independent validation studies.

methodsELISA was used to measure cellular and secreted FBLN3 in cell lines, in plasma of xenograft tumour-bearing mice, in plasma from two independent series of MPM and non-MPM patients and in pleural fluid from a third series. Diagnostic and prognostic potential of FBLN3 was assessed by receiver operating characteristics curve analysis and Kaplan-Meier method, respectively.

resultsFBLN3 was expressed in all MPM and benign mesothelial cell lines tested, and a correlation was observed between cellular protein expression and secreted levels. Human FBLN3 was detectable in plasma of tumour-bearing mice, suggesting that MPM cells contribute to levels of circulating FBLN3. Plasma FBLN3 was significantly elevated in MPM patients from the Sydney cohort, but not the Vienna cohort, but the diagnostic accuracy was low (63%, (95% CI: 50.1-76.4) and 56% (95% CI: 41.5-71.0), respectively). Although FBLN3 levels in pleural effusions were not significantly different between cases and controls, FBLN3 levels in pleural effusion fluid were found to be independently associated with prognosis (hazard ratio of 9.92 (95% CI: 2.14-45.93)).

conclusionsThese data confirm the potential prognostic value of pleural effusion FBLN3, but question the diagnostic value of this protein in MPM patients.

Indexed as

AdultAgedAged, 80 and overAnimalsBiomarkers, TumorCase-Control StudiesExtracellular Matrix ProteinsFemaleHeterograftsHumansMaleMesotheliomaMiceMice, NudeMiddle AgedNeoplasm ProteinsBiomarkers, TumorEFEMP1 protein, humanExtracellular Matrix ProteinsNeoplasm Proteins

Identifiers

PMID26263483
PMCPMC4578085

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.